



# HONDURAS

Number of new cases

**10 815**

Number of deaths

**7 011**

Number of prevalent cases (5-year)

**25 205**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	5 108 395	5 112 861	10 221 256
<b>Incidence*</b>			
Number of new cancer cases	5 051	5 764	10 815
Age-standardized incidence rate	131.2	127.7	128.0
Risk of developing cancer before the age of 75 years (cum. risk %)	14.0	13.0	13.4
Top 3 leading cancers (ranked by cases)**	Prostate Stomach Leukaemia	Breast Cervix uteri Thyroid	Breast Prostate Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	3 364	3 647	7 011
Age-standardized mortality rate	85.5	82.6	83.3
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.7	9.0	8.8
Top 3 leading cancers (ranked by deaths)**	Prostate Stomach Leukaemia	Cervix uteri Breast Leukaemia	Cervix uteri Stomach Prostate
<b>Prevalence*</b>			
5-year prevalent cases	10 741	14 464	25 205



## Top 5 most frequent cancers\*\*

**Males**




Total: 5 051

Rank	Cancer site	Number of cases	Percent
1st	Prostate	1 016	20.1%
2nd	Stomach	474	9.4%
3rd	Leukaemia	359	7.1%
4th	Lung	312	6.2%
5th	Colorectum	280	5.5%
-	Others	2 610	51.7%

Number of new cases in 2022, males, all ages

**Females**




Total: 5 764

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 209	21.0%
2nd	Cervix uteri	916	15.9%
3rd	Thyroid	389	6.7%
4th	Leukaemia	317	5.5%
5th	Colorectum	290	5.0%
-	Others	2 643	45.9%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 10 815

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 209	11.2%
2nd	Prostate	1 016	9.4%
3rd	Cervix uteri	916	8.5%
4th	Stomach	694	6.4%
5th	Leukaemia	676	6.3%
-	Others	6 304	58.3%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	1 209	1	11.2	3.0	504	4	7.2	1.2	3 272	13.0
Prostate	1 016	2	9.4	3.4	552	3	7.9	1.3	1 979	7.9
Cervix uteri	916	3	8.5	2.0	669	1	9.5	1.8	2 514	10.0
Stomach	694	4	6.4	1.0	631	2	9.0	1.0	1 047	4.2
Leukaemia	676	5	6.3	0.60	493	5	7.0	0.48	1 846	7.3
Colorectum	570	6	5.3	0.87	372	8	5.3	0.43	1 366	5.4
Lung	518	7	4.8	0.85	392	7	5.6	0.57	737	2.9
NHL	514	8	4.8	0.67	359	9	5.1	0.52	1 420	5.6
Thyroid	439	9	4.1	0.49	76	19	1.1	0.11	1 292	5.1
Liver	436	10	4.0	0.62	394	6	5.6	0.54	719	2.9
Brain CNS	431	11	4.0	0.45	351	10	5.0	0.41	1 388	5.5
Pancreas	292	12	2.7	0.45	269	11	3.8	0.38	312	1.2
Larynx	268	13	2.5	0.44	131	13	1.9	0.21	669	2.7
Hodgkin lymphoma	191	14	1.8	0.14	86	16	1.2	0.06	600	2.4
Ovary	184	15	1.7	0.40	152	12	2.2	0.33	474	1.9
Kidney	180	16	1.7	0.23	117	14	1.7	0.11	490	1.9
Bladder	145	17	1.3	0.20	72	20	1.0	0.08	357	1.4
Gallbladder	128	18	1.2	0.19	86	16	1.2	0.13	195	0.77
Oesophagus	115	19	1.1	0.16	110	15	1.6	0.13	148	0.59
Multiple myeloma	111	20	1.0	0.17	86	16	1.2	0.12	276	1.1
Corpus uteri	110	21	1.0	0.35	25	24	0.36	0.09	333	1.3
Testis	108	22	1.00	0.19	34	22	0.49	0.05	341	1.4
Lip, oral cavity	90	23	0.83	0.12	30	23	0.43	0.03	220	0.87
Penis	79	24	0.73	0.22	36	21	0.51	0.08	205	0.81
Melanoma	71	25	0.66	0.10	25	24	0.36	0.05	207	0.82
Salivary glands	45	26	0.42	0.06	16	26	0.23	0.02	122	0.48
Vulva	27	27	0.25	0.07	6	30	0.09	0.01	64	0.25
Vagina	19	28	0.18	0.06	8	28	0.11	0.03	47	0.19
Mesothelioma	16	29	0.15	0.02	16	26	0.23	0.02	19	0.08
Nasopharynx	14	30	0.13	0.02	7	29	0.10	0.01	41	0.16
Hypopharynx	12	31	0.11	0.01	3	32	0.04	0.00	9	0.04
Oropharynx	9	32	0.08	0.01	5	31	0.07	0.01	20	0.08
<b>All cancers</b>	<b>10 815</b>	-	-	<b>13.4</b>	<b>7 011</b>	-	-	<b>8.8</b>	<b>25 205</b>	-
<b>All cancers excl. NMSC</b>	<b>10 663</b>	-	-	<b>13.2</b>	<b>6 965</b>	-	-	<b>8.8</b>	<b>24 807</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** Francisco Morazan cancer registry

**Method:** Most recent rates from a single registry applied to 2022 population



### Mortality

**Country-specific data source:** National (WHO)

**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011–2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

